An arrhythmia is a problem with the speed or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. A heartbeat that is too fast is called tachycardia. A heartbeat that is too slow is called bradycardia. Most arrhythmias are harmless, but some can be serious or even life threatening. When the heart rate is too slow, too fast, or irregular, the heart may not be able to pump enough blood to the body. Lack of blood flow can damage the brain, heart, and other organs.
When treatment options dwindle or are exhausted, terminally ill-patients often opt for pain management and comfort over life-extending therapies.
When treatment options dwindle or are exhausted, terminally ill-patients often opt for pain management and comfort over life-extending therapies. However, a team of researchers from Wake Forest University Baptist Medical Center, University of Rochester Medical Center and Unity Health System, report that a lack of thorough understanding about the laws governing end-of-life care may be leaving many medical providers with an ethical dilemma and causing some terminally-ill patients considerable, unnecessary pain.
Exercise training is safe in heart failure patients, does not significantly reduce hospitalization or death, but is associated with several improved clinical outcomes, even in those already receiving optimal medical care, researchers reported at the American Heart Association's Scientific Sessions 2008. The Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) was presented as a late-breaking clinical trial.
UC San Diego Medical Center is currently enrolling patients in a Phase 2 clinical trial of an investigational drug for the treatment of advanced heart failure.
GE Healthcare continues to re-invent and re-imagine cardiology and the innovations that may help fuel the field through the future.
CV Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved a new, first line indication for Ranexa(R) (ranolazine extended-release tablets) for the treatment of chronic angina.
A study in the October 15 issue of the Journal of Clinical Sleep Medicine shows that respiratory sinus arrhythmia (RSA) is a significant predictor of insomnia in women with breast cancer and confirmed that longer nocturnal wake episodes were associated with a flatter diurnal cortisol slope.
The results of a post-hoc analysis of the data from the ATHENA study were presented today at the clinical trial update session of the European Society of Cardiology congress 2008, in Munich, Germany.
Catheter ablation is still associated with a substantial amount of complications, and more failure then sometimes reported. Perforation with catheters is especially important in atrial fibrillation. Robotic navigation could reduce these complications.
Sudden cardiac death (SCD) during sports activity is an uncommon, but catastrophic event. Different efforts to reduce the risk of SCD related to sports have been undertaken. What is the role of the exercise test in this context? What does a positive exercise test mean?
Researchers involved in the GISSI trial, concluded that simple, safe and cheap treatment with n-3 PUFA can provide a moderate beneficial advantage in terms of mortality and admission to hospital for cardiovascular reasons in patients with chronic heart failure, in a context of usual care.
Young competitive athletes are perceived by the general population to be the healthiest members of society. The possibility that highly trained athletes may have a potentially serious cardiac condition that can predispose to life-threatening tachyarrhythmias or sudden cardiac death seems paradoxical.
An emerging discipline of noninvasive cardiac imaging, molecular imaging, has evolved constantly in the last few years and is increasingly being translated from the preclinical to the clinical level.
A federal grant will allow Johns Hopkins researchers to purchase a powerful $2 million computer that will speed up their efforts to find new ways to diagnose and treat brain disease, heart illnesses, cancer and other medical ailments.
In the framework of Holst Centre, IMEC has further extended the functionality of its wireless ECG patch for cardiac monitoring. It added wave analysis software locally on the patch node.
The University of Rochester Medical Center (URMC) will collaborate with the U.S. Food and Drug Administration (FDA) to develop a national repository of data that will aid academic and industry researchers studying the electrical activity of the heart. In addition to helping researchers understand many cardiac problems, the data may aid the development of new tools to detect drugs that can have dangerous effects on the heart.
Six of every 100 patients who die in hospital do so as a consequence of an adverse drug reaction or, in other words, a fatal reaction to medicines. Those are the conclusions of a research carried out at the Department of Medicine of the University of Granada, in collaboration with the Clinical Hospital San Cecilio of Granada, by Alfredo Jose Pardo Cabello and directed by Professors Emilio Puche Canas (Department of Pharmacology) and Francisco Javier Gomez Jimenez (Department of Medicine).
The largest assessment of people with adult muscular dystrophy has identified risk factors that can lead to sudden death for individuals with the most common form of this disease.
Scientists at the University at Buffalo have created a mutant worm that changes color when it moves. The color change is generated by an optical sensor called stFRET. The sensor is composed of a pair of fluorescent molecules connected by a molecular spring that is inserted into structural proteins in the worm's cells.
State appeals courts in New Jersey and Texas on Thursday reversed two jury verdicts and a judgment on payment of legal fees in lawsuits related to the COX-2 inhibitor Vioxx that would have required Merck to pay about $37 million, Bloomberg/Washington Post reports (Van Voris/Voreacos, Bloomberg/Washington Post, 5/30).
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.